Cardiovascular Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease

Jun 6, 2025Journal of clinical gastroenterology

Heart and Blood Vessel Health in Fatty Liver Disease Linked to Metabolic Problems

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Over 25% of adults worldwide are affected by metabolic dysfunction-associated steatotic liver disease (MASLD).

MASLD can progress from asymptomatic fat accumulation in the liver to severe liver diseases such as cirrhosis and liver cancer.
There is a significant overlap between MASLD and cardiovascular disease (CVD), with both conditions sharing common risk factors like insulin resistance and obesity.
Impaired glucose metabolism and inflammation in blood vessels may increase the risk of heart-related issues in patients with MASLD.
Racial and ethnic disparities exist in the management of MASLD and CVD, indicating a need for personalized approaches to treatment.
Integrated care strategies are essential for addressing the heightened cardiovascular risks in individuals with MASLD.

AI simplified

Metabolic dysfunction-associated steatotic liver disease (MASLD), represents a growing global health concern, affecting over 25% of adults worldwide. The disease spectrum ranges from asymptomatic steatosis to advanced metabolic dysfunction-associated steatohepatitis (MASH), which predisposes individuals to severe complications, such as cirrhosis and hepatocellular carcinoma. MASLD shares a complex pathophysiological overlap with cardiovascular disease (CVD), with both conditions influenced by common risk factors, such as insulin resistance, obesity, dyslipidemia, and hypertension. These shared mechanisms, including impaired glucose metabolism, endothelial dysfunction, and vascular inflammation, significantly increase the risk of cardiovascular events in MASLD patients. Moreover, racial and ethnic disparities further complicate the management of MASLD and CVD, highlighting the need for tailored screening and intervention strategies. This review explores the intertwined relationship between MASLD and CVD, focusing on their shared risk factors, mechanisms, and the importance of integrated, multidisciplinary care to mitigate the elevated cardiovascular risks in this high-risk patient population. Early diagnosis, effective risk stratification, and comprehensive management are crucial for reducing long-term morbidity and mortality in patients with MASLD.

Full Text

Full text is available at the source.

View full text ↗

Cardiovascular Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief